156925-22-3

Basic information

• Product Name: ((R)-morpholin-2-yl)methanol
• Synonyms: (R)-Morpholin-2-ylmethanol hydrochloride;(S)-2-hydroxymethylmorpholine HCl;(2R)-morpholin-2-ylmethanol;(R)--2-Hydroxymethylmorpholine hydrochloride;(R)-3-Hydroxymethylmorpholine hydrochloride;(R)-2-morpholinylmethanol;2-MorpholineMethanol, (2R)-;(R)-Morpholin-2-ylMethanol-HCl
• CAS NO: 156925-22-3
• Molecular Formula: C₅H₁₁NO₂
• Molecular Weight: 117.14634
• Product Categories: pharmacetical
• Mol File: 156925-22-3.mol

Chemical Properties

• Boiling Point: 220.122 °C at 760 mmHg
• Flash Point: 86.927 °C
• Appearance: /Solid
• Density: 1.045 g/cm³
• Vapor Pressure: 0.024mmHg at 25°C
• Refractive Index: 1.441
• PKA: 14.36±0.10(Predicted)
• CAS DataBase Reference: ((R)-morpholin-2-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: ((R)-morpholin-2-yl)methanol(156925-22-3)
• EPA Substance Registry System: ((R)-morpholin-2-yl)methanol(156925-22-3)

Safety Data

• Hazardous Substances Data: 156925-22-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
((R)-morpholin-2-yl)methanol is used as a building block for the synthesis of various pharmaceutical compounds. Its unique stereochemistry and reactivity enable the development of innovative drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
((R)-morpholin-2-yl)methanol is utilized as a key intermediate in the production of agrochemicals, such as pesticides and herbicides. Its ability to undergo various chemical transformations allows for the creation of effective and targeted agrochemicals.
Used in Fine Chemicals Industry:
((R)-morpholin-2-yl)methanol is employed as a versatile intermediate in the synthesis of fine chemicals, including specialty chemicals, fragrances, and flavorings. Its molecular structure and reactivity contribute to the development of high-quality and diverse chemical products.
Used in Organic Synthesis:
((R)-morpholin-2-yl)methanol is used as a reagent in organic synthesis, facilitating various chemical reactions and transformations. Its unique properties make it a valuable component in the synthesis of complex organic molecules and compounds.

InChI:InChI=1/C5H11NO2/c7-4-5-3-6-1-2-8-5/h5-7H,1-4H2/t5-/m1/s1

Upstream product

• 919286-64-9 (R)-2-chloro-N-(2,3-dihydroxypropyl)acetamide 
• 943442-96-4 (R)-N-benzyl-2-(hydroxymethyl)morpholine 
• 1022915-31-6 (R)-hexahydro-4-phenylmethyl-1,4-oxazepin-6-ol 
• 919286-65-0 (R)-6-(hydroxymethyl)morpholin-3-one 
• 205242-68-8 N-Benzyl-N-((R)-3-benzyloxy-2-hydroxy-propyl)-2-chloro-acetamide 
• 205242-59-7 (R)-4-Benzyl-6-benzyloxymethyl-morpholin-3-one 
• 205242-60-0 (R)-N-benzyl-3-benzyloxymethylmorpholine 
• 135065-70-2 (2R)-2-[(benzyloxy)methyl]morpholine 

Downstream Products

• 861848-98-8 (R)-N-(3,4-dichlorobenzyl)-2-hydroxymethyl-morpholine 
• 135065-64-4 tert-butyl (2R)-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)morpholine-4-carboxylate 
• 2227425-05-8 (R)-3-chloro-7-(2-(hydroxymethyl)morpholino)-2-methyl-5-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridine-6-carbonitrile 
• 1414940-50-3 C₂₃H₂₈N₂O₃ 
• 1414940-48-9 C₂₂H₂₅ClN₂O₃ 
• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 
• 156925-20-1 (R)-(-)-<4-(4-fluorobenzyl)-2-morpholinyl>methyl p-toluenesulfonate 
• 156334-89-3 (S)-(-)-<4-(4-fluorobenzyl)-2-morpholinyl>methylamine 
• 135912-24-2 Toluene-4-sulfonic acid (R)-4-trityl-morpholin-2-ylmethyl ester 
• 132073-85-9 ((R)-4-Trityl-morpholin-2-yl)-methanol 

Relevant articles and documents

MORPHOLINO COMPOUNDS, USES AND METHODS

The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7/s

MORPHOLINO COMPOUNDS, USES AND METHODS

The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7/s

PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT

The present invention relates to a production method of a 2-hydroxymethylmorpholine salt, which includes crystallization from a solution containing 2-hydroxymethylmorpholine represented by the following formula (1) 1,4-oxazepane compound represented by th

Intramolecular reductive amination strategy to the synthesis of (R)-N-Boc-2-hydroxymethylmorpholine, N-(3,4-dichlorobenzyl)(R)-2-hydroxymethylmorpholine, and (R)-2-benzylmorpholine

A concise high yielding enantioselective synthesis of (R)-N-Boc-2-hydroxymethylmorpholine, N-(3,4-dichlorobenzyl)(R)-2-hydroxymethylmorpholine, and (R)-benzylmorpholine has been achieved by employing proline-catalyzed asymmetric α-aminooxylation of aldehyde and palladium-catalyzed intramolecular reductive amination of azido aldehyde as the key steps.

PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin- 2 - yl -pyridin- 2 -yl -amine and pyrazine - 2 - yl -pyrimidin- 4 - yl -amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1 ) kinase function The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1. that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or Il inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisiπq radiation. wherein: -X= is independently -CRA5= or -N=; and the rest of the substituents are as specified in the claims.

CYSTEINE PROTEASE INHIBITORS

Stereoisomers of the formula (III) wherein R is H or C1-C3 optionally halo-substituted alkyl; or pharmaceutically acceptable salts, hydrates or N-oxides thereof have utility in the treatment of disorders mediated by inappropriate exp

(R)-(+)-2-[[[3-(morpholinomethyl)-2H-chromen-8-yl]oxy]methyl]morpholine methanesulfonate: A new selective rat 5-hydroxytryptormine(1b) receptor antagonist

In the search for new 5-hydroxytryptamine (5-HT) receptor antagonists it was found that the compound (R)-(+)-2-[[[3-(morpholinomethyl)-2H-chromen-8- yl]oxy]methyl]morpholine methanesulfonate, (R)-25, is a selective rat 5- hydroxytryptamine(1B) (r5-HT(1B)) receptor antagonist. The binding profile showed a 13-fold preference for r5-HT(1B) (Ki = 47 ± 5 nM; n = 3) vs bovine 5-HT(1B) (Ki = 630 nM; n = 1) receptors. The compound had very low affinity for other monoaminergic receptors examined. The r5-HT(1B) receptor antagonism was demonstrated by the potentiation of the K+-stimulated release of [3H]- 5-HT from superfused rat brain slices in vitro, an effect that was antagonized by addition of 5-HT to the superfusion fluid. (R)-25 at 20 mg/kg sc enhanced the 5-HT turnover in four rat brain regions (hypothalamus, hippocampus, striatum, and frontal cortex) with about 40% measured as the 5- HTP accumulation after decarboxylase inhibition with 3- hydroxybenzylhydrazine. At 3 mg/kg sc (R)-25 produced a significant increase in the number of wet dog shakes in rats, a 5-HT(2A)/5-HT(2C) response that was abolished by depletion of 5-HT after pretreatment with the tryptophan hydroxylase inhibitor p-chlorophenylalanine. The observations show that (R)- 25, by inhibiting terminal r5-HT(1B) autoreceptors, increases the 5-HT turnover and the synaptic concentration of 5-HT.

Synthesis and biological activities of the optical isomers of (±)-4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]me thyl]benzamide (Mosapride)

The enantiomers, (S)-(-)-1 and (R)-(+)-1, of (+)-4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]met hyl]benzamide (mosapride) [(+)-1], a new and selective gastroprokinetic agent, were prepared from optically active [4-(4-fluorobenzyl)-2-morpholinyl]methylamines (S)-(-)-4 and (R)-(+)-4, respectively. The requisite (S)-(-)-4 and (R)-(+)-4 were prepared by optical resolution of [4-(4-fluorobenzyl)-2-morpholinyl]methyl p-toluenesulfonate [(+)-5] using (-)- and (+)-N-(p-toluenesulfonyl)glutamic acids, followed by amination of the tosyloxy groupe of (R)-(-)-5 and (S)-(+)-5, respectively. The absolute configurations of (R)-(-)-5 and (S)-(+)-5 were determined on the basis of an asymmetric synthesis of (R)-(-)-5 from (S)-(+)-benzyl glycidyl ether [(S)-(+)-11]. Mosapride and its enantiomers, (S)-(-)-1 and (R)-(+)-1, were essentially equipotent in serotonin 5-HT4 receptor agonistic activity on the electrically evoked contractions in isolated guinea pig ileum.